Emerging therapies like GOCOVRI, JM-010, and NLX-112 are anticipated to drive growth in the Parkinson’s Disease Levodopa-Induced Dyskinesia market in the coming years.
DelveInsight has launched a new report on "Parkinson's Disease Levodopa-Induced Dyskinesia - Market Insights, Epidemiology, and Market Forecast-2034” that delivers an in-depth understanding of the Parkinson's Disease Levodopa-Induced Dyskinesia, historical and forecasted epidemiology as well as the Parkinson's Disease Levodopa-Induced Dyskinesia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Request for a detailed sample report @ https://www.delveinsight.com/report-store/parkinsons-disease-levodopa-induced-dyskinesia-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Some of the key facts of the Parkinson's Disease Levodopa-Induced Dyskinesia Market Report:
-
In 2023, the U.S. market for Parkinson’s Disease Levodopa-Induced Dyskinesia (PD-LID) treatments was valued at approximately USD 900 billion. Supernus Pharmaceuticals’ GOCOVRI, approved by the FDA in 2021 for managing OFF episodes in patients on levodopa therapy, also helps address dyskinesia and other motor complications. However, it carries potential side effects such as hallucinations, dizziness, dry mouth, swelling, constipation, falls, and orthostatic hypotension.
-
While several treatment options exist for PD-LID, none provide consistent or universal relief, highlighting the need for more targeted therapies. Responses to levodopa and the onset of dyskinesia differ greatly between patients, with some developing symptoms early in their treatment course and others only after years, making management unpredictable.
-
Encouragingly, multiple companies are advancing new therapies, including NLX-112 (Neurolixis SAS/Gala Laboratories), JM-010 (Bukwang Pharmaceutical/Contera Pharma), KETARX (PharmaTher, ketamine-based), and AV-101 (Vistagen). These emerging treatments are expected to positively shape the PD-LID market between 2024 and 2034.
-
Among EU4 and the UK in 2023, Germany reported the highest number of PD-LID cases (~67,000), followed by France (~56,000) and Italy (~47,000). In the U.S., ~240,000 patients were affected, including 88,000 with off-period dystonia, 59,000 with diphasic dyskinesia, and the remainder with peak-dose dyskinesia. With an aging population, these figures are projected to rise significantly by 2034.
-
Recent regulatory milestones reflect ongoing innovation in Parkinson’s disease care. In March 2025, MedRhythms’ MR-005 Movive neurorehabilitation system was designated by the FDA as a Class II Rx-only medical device for gait and motor function rehabilitation. In February 2025, Medtronic gained FDA approval for its BrainSense™ Adaptive Deep Brain Stimulation (aDBS), marking progress in neuromodulation therapy. That same month, Supernus Pharmaceuticals received FDA approval for ONAPGO (apomorphine hydrochloride), the first subcutaneous infusion device for managing motor fluctuations. Earlier, in October 2024, AbbVie secured FDA approval for VYALEV (foscarbidopa/foslevodopa), the first 24-hour continuous subcutaneous infusion of a levodopa-based therapy.
-
Key companies such as PharmaTher, Neurolixis SAS, Gala Laboratories, Bukwang Pharmaceutical, Contera Pharma, Vistagen, Ipsen Pharma, Newron Pharmaceuticals, Zambon Pharmaceuticals, Celon Pharma SA, and others are advancing next-generation PD-LID treatments. Promising pipeline candidates include GOCOVRI, JM-010, and NLX-112 (befiradol), which are expected to enhance the treatment landscape in the years ahead.
Key benefits of the Parkinson's Disease Levodopa-Induced Dyskinesia market report:
-
Parkinson's Disease Levodopa-Induced Dyskinesia market report covers a descriptive overview and comprehensive insight of the Parkinson's Disease Levodopa-Induced Dyskinesia Epidemiology and Parkinson's Disease Levodopa-Induced Dyskinesia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
-
The Parkinson's Disease Levodopa-Induced Dyskinesia market report provides insights on the current and emerging therapies.
-
Parkinson's Disease Levodopa-Induced Dyskinesia market report provides a global historical and forecasted market covering drug outreach in 7MM.
-
The Parkinson's Disease Levodopa-Induced Dyskinesia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Parkinson's Disease Levodopa-Induced Dyskinesia market.
Got queries? Click here to know more about the Parkinson's Disease Levodopa-Induced Dyskinesia Market Landscape
Parkinson's Disease Levodopa-Induced Dyskinesia Overview
Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disorder characterized mainly by motor symptoms such as bradykinesia (slowness of movement), tremors, and muscle rigidity. Beyond these hallmark signs, patients often face cognitive decline, psychiatric disturbances, and treatment-related complications like levodopa-induced dyskinesia (LID).
Levodopa (L-DOPA) remains the gold standard for symptom management in PD, but prolonged use frequently results in involuntary, uncontrolled movements known as dyskinesias. These may initially be mild but can progress into severe motor complications that substantially impair quality of life. Studies show that more than half of patients develop LID after five years of continuous levodopa therapy.
Clinically, LID manifests in multiple ways, most commonly as chorea or choreoathetosis. Other patterns include myoclonus, ballism, and akathisia—a form of pronounced motor restlessness. Less frequent presentations involve exaggerated, high-stepping gait, rapid alternating leg movements (RAMs), eyelid spasms (blepharospasm), and mixed abnormal movement disorders.
Parkinson's Disease Levodopa-Induced Dyskinesia Market Outlook
Current therapeutic approaches for Parkinson’s disease Levodopa-Induced Dyskinesia (PD-LID) include both pharmacological and non-pharmacological strategies. Non-drug options range from bandage contact lenses and topical ocular agents (cycloplegics, NSAIDs, steroids, lubricants) to oral pain medications. Acute pain is typically managed with non-opioid drugs such as NSAIDs or acetaminophen, though opioids or topical anesthetics may be used in select cases, especially for pain linked to surgery, injury, infection, or inflammation.
In 2017, the U.S. FDA approved GOCOVRI (amantadine) extended-release capsules as the first therapy for PD patients receiving levodopa-based treatment. This approval was expanded in 2021 to include extended-release tablets as an adjunct for levodopa/carbidopa patients experiencing OFF episodes. To date, GOCOVRI remains the only FDA-approved drug specifically indicated for PD-LID.
Meanwhile, pharmaceutical companies continue advancing new therapies to address unmet needs in PD-LID. Factors such as treatment innovations, the rising prevalence of Parkinson’s disease, supportive regulatory changes, and increasing awareness among clinicians and patients are expected to shape the market’s growth trajectory in the coming years.
Discover how the parkinson’s disease levodopa-induced dyskinesia market is rising in the upcoming years
Parkinson's Disease Levodopa-Induced Dyskinesia Marketed Drugs and Key Companies
-
GOCOVRI: Supernus Pharmaceuticals
Parkinson's Disease Levodopa-Induced Dyskinesia Emerging Drugs and Key Companies
-
JM-010: Bukwang Pharmaceutical/Contera Pharma
-
NLX-112 (befiradol): Neurolixis SAS/Gala laboratories
To know which therapies are driving the parkinson’s disease levodopa-induced dyskinesia market, visit: https://www.delveinsight.com/sample-request/parkinsons-disease-levodopa-induced-dyskinesia-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Scope of the Parkinson's Disease Levodopa-Induced Dyskinesia Market Report
-
Study Period: 2020-2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Parkinson's Disease Levodopa-Induced Dyskinesia Companies: PharmaTher Inc., Neurolixis SAS, Gala laboratories, Bukwang Pharmaceutical, Contera Pharma, Vistagen, Ipsen Pharma, Newron Pharmaceuticals, Zambon Pharmaceuticals, Celon Pharma SA, and others
-
Key Parkinson's Disease Levodopa-Induced Dyskinesia Therapies: IGOCOVRI, JM-010, NLX-112 (befiradol), and others
-
Parkinson's Disease Levodopa-Induced Dyskinesia Therapeutic Assessment: Parkinson's Disease Levodopa-Induced Dyskinesia current marketed and Parkinson's Disease Levodopa-Induced Dyskinesia emerging therapies
-
Parkinson's Disease Levodopa-Induced Dyskinesia Market Dynamics: Parkinson's Disease Levodopa-Induced Dyskinesia market drivers and Parkinson's Disease Levodopa-Induced Dyskinesia market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
-
Parkinson's Disease Levodopa-Induced Dyskinesia Unmet Needs, KOL's views, Analyst's views, Parkinson's Disease Levodopa-Induced Dyskinesia Market Access and Reimbursement
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Parkinson's Disease Levodopa-Induced Dyskinesia Patient Share (%) Overview at a Glance
5. Parkinson's Disease Levodopa-Induced Dyskinesia Market Overview at a Glance
6. Parkinson's Disease Levodopa-Induced Dyskinesia Disease Background and Overview
7. Parkinson's Disease Levodopa-Induced Dyskinesia Epidemiology and Patient Population
8. Country-Specific Patient Population of Parkinson's Disease Levodopa-Induced Dyskinesia
9. Parkinson's Disease Levodopa-Induced Dyskinesia Current Treatment and Medical Practices
10. Unmet Needs
11. Parkinson's Disease Levodopa-Induced Dyskinesia Emerging Therapies
12. Parkinson's Disease Levodopa-Induced Dyskinesia Market Outlook
13. Country-Wise Parkinson's Disease Levodopa-Induced Dyskinesia Market Analysis (2020–2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Parkinson's Disease Levodopa-Induced Dyskinesia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Click here to read more about Parkinson's Disease Levodopa-Induced Dyskinesia Market Outlook 2034
Related Reports:
Parkinson's Disease Levodopa-Induced Dyskinesia Pipeline Insights, DelveInsight
"Parkinson's Disease Levodopa-Induced Dyskinesia Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Parkinson's Disease Levodopa-Induced Dyskinesia market. A detailed picture of the Parkinson's Disease Levodopa-Induced Dyskinesia pipeline landscape is provided, which includes the disease overview and Parkinson's Disease Levodopa-Induced Dyskinesia treatment guidelines.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
